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Introduction
Acrylonitrile  is  used  in  the  production  of  acrylic  and 
modacrylic fibers, copolymers, adipinonitrile, acrylamide 
and other industrial chemicals (IARC, 1979; IARC, 1999). 
General population exposure to acrylonitrile is limited to 
tobacco smoke, accidental fires, and residual acrylonitrile 
in commercial polymeric material (Leonard et al., 1999). 
Tobacco  smoke  is  by  far  the  major  non-occupational 
source for acrylonitrile exposure.
Ranges for mainstream smoke yields were reported 
to amount to 4.4 – 11.9 and 7.8 – 39.1 µg/cigarette when 
machine smoked with ISO and Massachusetts smoking 
parameters, respectively (IARC, 2004). The correspond-
ing sidestream smoke yields amount to 24.1 – 85.6 µg/
cigarette (IARC, 2004). The ambient air concentration of 
acrylonitrile due to environmental tobacco smoke (ETS) 
was estimated to be 0.1-1.9 µg/m3 (Miller et al., 1998; 
Jenkins et al., 2000).
The  International  Agency  for  Research  on  Cancer 
(IARC) has classified acrylonitrile as a ‘possible human 
carcinogen’  (2B)  (IARC,  1999).  The  evidence  for  this 
classification is mainly based on rat inhalation studies 
which reported nervous system, mammary, and hepatic 
tumors (IARC, 1999). Acrylonitrile was also shown to be 
mutagenic in some in vitro test systems, including the 
Ames assay (Leonard et al., 1999). At high doses, acry-
lonitrile is toxic to the central nervous system, gastro-
intestinal tract, and adrenals (Leonard et al., 1999; Thier 
et al., 2000).
Once absorbed in the body, acrylonitrile is metabo-
lized through: (i) Epoxidation to glycidonitrile, which 
in  turn  can  form  DNA  and  protein  adducts  and  sev-
eral  other  metabolites  including  cyanide  (Figure  1) 
(Lambotte-Vandepaer et al., 1985; Fennell et al., 2000). (ii) 
Nucleophilic reaction with glutathione (GSH) and pro-
teins (Figure 1) (Lambotte-Vandepaer et al., 1985; Fennell 
et al., 1991; Sumner et al., 1997; Thier et al., 2000).
Biomarkers, 2011; 16(1): 89–96
Address for Correspondence:  Dr Emmanuel Minet, British American Tobacco, Group Research and Development, Regents Park Road, Southampton, SO15 
8TL, UK, Phone: +44-(0)2380 588 997, Fax: +44-(0)2380 793 076, E-mail: emmanuel_minet@BAT.com
original arTiClE
Urinary excretion of the acrylonitrile metabolite 
2-cyanoethylmercapturic acid is correlated with a 
variety of biomarkers of tobacco smoke exposure and 
consumption
Emmanuel Minet1*, Francis Cheung1, Graham Errington1, Katharina Sterz2, and Gerhard Scherer2
1British American Tobacco, Group Research and Development, Regents Park Road, Southampton, SO15 8TL, UK, and 
2Analytisch-biologisches Forschungslabor GmbH, Goethestrasse 20, 80336 Munich, Germany 
abstract
Acrylonitrile is an IARC class 2B carcinogen present in cigarette smoke. Urinary 2-cyanoethylmercapturic 
acid (CEMA) is an acrylonitrile metabolite and a potential biomarker for acrylonitrile exposure. The objective 
of this work was to study the dose response of CEMA in urine of non-smokers and smokers of different ISO 
tar yield cigarettes. We observed that smokers excreted >100-fold higher amounts of urinary CEMA than 
non-smokers. The CEMA levels in smokers were significantly correlated with ISO tar yield, daily cigarette con-
sumption, and urinary biomarkers of smoke exposure. In conclusion, urinary CEMA is a suitable biomarker 
for assessing smoking-related exposure to acrylonitrile.
Keywords:  Acrylonitrile; 2-cyanoethylmercapturic acid (CEMA); cigarette smoking; exposure
(Received 19 August 2010; revised 08 October 2010; accepted 16 October 2010)
ISSN 1354-750X print/ISSN 1366-5804 online © 2011 Informa UK, Ltd.
DOI: 10.3109/1354750X.2010.533287 http://www.informahealthcare.com/bmk
Biomarkers
2011
16
1
89
96
19 August 2010
08 October 2010
16 October 2010
1354-750X
1366-5804
© 2011 Informa UK, Ltd.
10.3109/1354750X.2010.533287
BMK
533287
TBMK90    Emmanuel Minet et al.
As final products of the reaction with GSH, a number 
of mercapturic acids are formed which are excreted into 
the urine, the most important of which is 2-cyanoethyl-
mercapturic acid (CEMA) (Figure 1) (Fennell et al., 1991; 
Sumner et al., 1997).
In order to test a biomarker’s suitability, an assess-
ment of specificity, sensitivity, reproducibility, and the 
qualification of a dose-response relationship is required. 
Recently, Schettgen et al. reported 120-fold higher urinary 
CEMA  levels  in  smokers  compared  to  non-smokers 
(Schettgen et al., 2009). Furthermore, a gradual increase 
in CEMA excretion was correlated to urinary cotinine 
(Schettgen et al., 2009). In 2010, Scherer and colleagues 
described a method to quantify acrylonitrile and other 
alkylating agents (Scherer et al., 2010). It was applied to 
a group of smokers of conventional cigarette products, a 
group of highly activated carbon filter cigarette smokers, 
and a group of quitters. Although a difference could be 
2-cyanoethylvaline (CEVal)
Hb adduct
Prot
NH
NH
SS
N N
NH
NH
NH NH OH
OH
OH
OH
OH
O
O
S
S
S
S
S
N
N
NH
NH
NH
NH
NH
HO
HO
HO
HO
HO
HO
HO
HO
H2N
H2N
H2N
O
O
O O
O
O
O O
O
O
CN−
SCN−
O
O
N
N
O
O O O
O
O
O
O OH
HO
NH
N
2-cyanoethylmercapturic
acid (CEMA)
1-cyano-2-
hydroxyethylmercapturic
acid
DNA and protein
adducts
GSH
GSH
GSH
GST
acrylonitrile
glycidonitrile
carboxymethylmercapturic
acid
2-hydroxyethylmercapturic
acid
Hb
Figure 1.  Simplified  metabolic pathway of acrylonitrile, modified from Leonard et al., 1999. GSH:glutathione, GST: glutathione S-transferase, 
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observed between the groups this work did not address 
the dose response relationship of CEMA as biomarker and 
the correlation with other cigarette smoke biomarkers.
Here, we investigated the dose-response relationship 
between  smoking-related  acrylonitrile  exposure  and 
CEMA excretion. The level of urinary CEMA in smokers 
of different ISO tar yield cigarettes (1, 4, and 10 mg) were 
compared with a variety of nicotine exposure biomarkers 
including Tneq (total nicotine equivalent) and nicotine 
MLE  (mouth  level  exposure).  Correlations  were  also 
established with two biomarkers of exposure to smoke 
toxicants, namely 3-HPMA (3-hydroxypropyl mercapturic 
acid), and NNAL, which are metabolites of acrolein and 
NNK (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone), 
respectively. The results presented in this report show 
that urinary CEMA is a robust biomarker of exposure.
Materials and Methods
Chemicals and standards - N-Acetyl-S-(2-cyanoethyl)-
L-cysteine  (2-cyanoetehylmercapturic  acid,  CEMA), 
and [d3]-N-acetyl-S-(2-cyanoethyl)-L-cysteine (CEMA-
d3) were purchased from Toronto Research Chemicals, 
North  York,  Ontario,  Canada.  The  supplier  stated  a 
chemical  purity  of  98  %  or  greater  for  all  reference 
compounds. Results of this study were not corrected 
for purity.
Ammonium  formate  (≥  99  %)  was  obtained  from 
Sigma-Aldrich, Taufkirchen, Germany. Formic acid (98 
– 100 %) and acetonitrile (for HPLC) were purchased 
from Merck, Darmstadt, Germany. Deionized water was 
prepared with Seradest equipment (Munich, Germany). 
All chemicals were of analytical grade or higher.
Analytical methods - Smoke chemistry – Three US 
king size commercial brands of 1, 4.7, and 10.5 mg/ cig 
ISO tar yields were used in this study. These products 
are referred as 1, 4, and 10 mg cigarettes, respectively. 
Smoke chemistry for the 1, 4, and 10 mg ISO Tar products 
was analysed by GC-MS following a method adapted 
from Dong and colleagues (Dong et al., 2000). Briefly, 
conditioned cigarettes were smoked (three replicates) 
using a Borgwaldt RM20/CS smoking machine set to 
ISO (35 ml puff volume, 2 sec puff duration every 60 sec) 
and  Massachusetts  (45 ml  puff,  2 sec  puff  duration 
every 30 sec, 50% vent holes blocked) standard smoking 
regimes (International Organization for Standardization, 
2000; Massachusetts General Law, 1997). The generated 
smoke passed through a 44mm Cambridge Filter Pad 
(CFP),  to  remove  particulates,  before  the  remaining 
vapour phase was collected in a 3L Tedlar bag. Internal 
standard, deuterated acrylonitrile, was added before a 
precise volume (0.5mL) was injected into a GC/MS sys-
tem (Agilent 6890) fitted with a RTX-VMS column (length 
30 m, 0.32 mm i.d., 1.8µm film thickness) for separation 
and analysis. Acrylonitrile was detected and quantified 
using a target ion at 52 m/z and two qualifier ions at 53 
and 38 m/z.
Analytical  methods  –  Urinary  biomarkers  -  The 
determination of CEMA in urine was performed using 
a  method  adapted  from  Schettgen  et  al.  (Schettgen 
et al., 2009), and validated according to the U.S. Food 
and Drug Administration guidelines for bioanalytical 
methods (FDA, 2001). In brief, 0.5 ml 50 mM ammo-
nium formate buffer, pH 2.5 and 10 µl internal stand-
ard  (IS)  solution  (100 ng  CEMA-d3  in  0.1  %  formic 
acid) were added to 0.5 ml of urine vortexed and cen-
trifuged (3000 × g, 10 min). Fifty (50) µl of this mixture 
was  injected  into  an  LC-MS/MS  system,  consisting 
of a Model 1200 HPLC device (Agilent Technologies, 
Waldbronn,  Germany)  and  an  atmospheric  pressure 
ionization triple quadrupole mass spectrometer (Sciex 
API 5000, Applied Biosystems, Darmstadt, Germany). 
RAM  (Restricted  Access  Material),  chromatographic 
column,  and  mobile  phases  were  as  described  in 
Schettgen et al., 2009. Gradient and valve positions are 
summarized in Table 1.
Negative electrospray ionization (ESI-) was applied, 
and the MS/MS system was run in the multi-reaction 
monitoring (MRM) mode. Retention times as well as the 
quantifier and qualifier mass transitions of the analyte 
(CEMA) and the IS (CEMA-d3) are shown in Table 2. The 
mean quantifier/qualifier ratio was 0.7, acceptance crite-
ria were +/-25%, which were met by all samples analyzed. 
LOD was estimated by extrapolating the signal to noise 
ratio S/N = 3 from a non-smoker urine sample with low 
CEMA background.
The method was calibrated by spiking non-smokers 
pooled  urine  with  CEMA  at  concentrations  of  2.0  to 
1000 ng/ml. The analyte/IS ratio of the unspiked urine 
(zero calibrator) was subtracted from each calibrator. 
Linear regression was applied for the calculation of the 
calibration function and the regression line was forced 
through the origin.
Table 1.  Column switching and gradient program of the LC-MS/MS 
for CEMA in urine. Mobile phase: A: water, 0.1% formic acid; B: 40% 
A and 60% acetonitrile v/v.
Time (min)
Mobile  
phase A (%) Valve position Chromatographic step
0.0 80 A RAM sample loading
0.5 80 B Backflushing – RAM 
sample clean up
1.3 80 A Injection
2.0 80 A Separation
8.0 60 A
10.0 50 A
11.5 0 A
17.0 0 A Washing
21.0 80 A
25.0 80 A Reconditioning92    Emmanuel Minet et al.
Mouth level exposure (MLE) to nicotine was esti-
mated  using  previously  described  methodology 
(Shepperd et al., 2006; St Charles et al., 2006). Briefly, 
filter tips are collected and nicotine is extracted with 
methanol  for  quantification  by  gas  chromatography 
which provides an estimate of human-smoked ciga-
rette yields. Urinary total nicotine equivalents (Tneq) is 
  calculated as the sum of urinary nicotine, cotinine, and 
trans-3′-hydroxycotinine  following  β-glucuronidase 
treatment (Xu et al., 2004), 4-(Methylnitrosamino)-1-
(3-Pyridyl)-1-Butanol (NNAL), and 3-hydroxypropylm-
ercapturic acid (3-HPMA) were also determined, using 
previously  described  methodologies  (Scherer  et  al., 
2007; Shepperd et al., 2009).
Urine Samples - One hundred and ninety (190) 24h-
urine samples stored at -25 °C were taken from a pre-
vious clinical study performed in Germany (Shepperd 
et al., 2009). Twenty four (24) hours urine samples were 
obtained  from  healthy  smoking  (n = 140)  and  non-
smoking (n = 50) volunteers. The smokers belonged to 
three groups, smoking cigarettes with 10 mg (n = 47), 
4 mg (n = 45), or 1 mg (n = 48) tar as nicotine-free dry 
particulate  matter  (NFDPM),  determined  according 
to  the  ISO  standard  smoking  regime.  Demographic 
analysis  showed  a  normal  distribution  for  the  BMI 
(body mass index) with no differences between groups; 
however, more females (63%) were recruited in the 1 mg 
product category and more males were recruited in the 
non-smoker group (62%) and the 10 mg group (68%). 
The urine samples were initially collected in the course 
of 2006 during a residential visit to the clinic. Each 
group stayed at the clinic at different days to ensure 
compliance and limit environmental exposure for the 
non-smoker group. Biomarker analyses were performed 
in 2007 for MLE, Tneq, 3-HPMA, and NNAL and the 
data was reported in Shepperd et al., 2009. CEMA data 
was acquired in 2009 following analysis of the stored 
samples. Freeze thaw cycles and long-term storage sta-
bility for CEMA for two months (Scherer et al., 2010) 
and up to one year (data not shown) did not indicate 
any instability.
The  study  protocol  and  informed  consent  forms 
were  approved  by  the  Ethics  Committee  of  the 
Ärztekammer  Hamburg,  Germany  and  the  clini-
cal  study  was  conducted  in  accordance  with  the 
World  Medical  Association  Declaration  of  Helsinki 
(World Medical Association, 2004) and International 
Conference  on  Harmonisation  (ICH)  Guidelines  for 
Good Clinical Practice (GCP) (International Conference 
on Harmonization, 1996).
Statistics - All statistical analyses were carried out 
with  MINITAB  v15.1  (MINITAB  Inc.,  Quality  Plaza, 
1829 Pine Hall Rd, State College, PA 16801-3008, USA). 
Summary statistics were computed for urinary CEMA, 
and other markers of smoke exposure (MLE to nicotine, 
Tneq, NNAL, 3-HPMA, and cigarettes per day) taken 
from the study by Shepperd et al., 2009. A correlation 
matrix was produced to test relationships across the 
different CEMA and markers of exposure. Analysis of 
variance was carried out with ISO tar yield as a factor fol-
lowed by post ANOVA comparisons (Tukey’s HSD test). 
Tukey’s HSD test determines which means amongst a 
set of means differs from the rest (Altman., 1991).
Results
Smoke  chemistry  -  To  demonstrate  that  the  selected 
products  (1,  4,  and  10 mg  ISO  tar)  yielded  different 
amounts of acrylonitrile, mainstream smoke acrylonitrile 
levels were quantified under the ISO and Massachusetts 
smoking regime. The results are reported in Table 3 and 
showed an increase in acrylonitrile levels between the 
lower and the higher tar band products and according 
to smoking regime intensity.
Performance of the LC-MS/MS method for CEMA 
in urine - Performance data for the CEMA analytical 
method are summarized in Table 4. Ranges for intra- and 
inter-day precisions were 0.9 – 2.6 and 2.9 – 5.6 %, respec-
tively. Accuracy of method was 92.4 % at high (300 ng/
ml) and 102.5 % at low (3.0 ng/ml) levels. LOD and LOQ 
were at 0.06 and 0.17 ng/ml, respectively, allowing quan-
tification of CEMA in all urine samples, including that of 
non-smokers.
Urinary  CEMA  excretion  in  non-smokers  and 
 smokers - Urinary CEMA in non-smokers and smokers 
of 1, 4, and 10 mg ISO tar band products was quantified 
using the LC-MS/MS method described above. CEMA 
levels in urine of non-smokers were significantly lower 
than in urine of smokers (Figure 2) and mean CEMA lev-
els increased with the ISO tar levels (Figure 2) (Table 5). 
Table 3.  Mainstream acrylonitrile content in smoke of 1, 4, and 10 mg 
ISO tar products used in this study. Data is reported for the standard 
ISO and Massachusetts smoking regimes.
ISO Tar yields (mg/cig) 1 4.7 10.5
Acrylonitrile ISO regime (µg/cig) 0.72 ± 0.07 2.89 ± 0.17 7.56 ± 0.37
Massachusetts Tar yields (mg/cig) 7 13.6 24
Acrylonitrile Massachusetts 
regime (µg/cig)
9.21 ± 0.46 12.36 ± 0.46 18.18 ± 0.4
Table 2.  Retention times (RT) and mass transitions for CEMA and the 
internal standard (CEMA-d3).
  RT (min) Parent ion (m/z) Daughter ion (m/z)
CEMA quantifier 13.85 215 162
CEMA qualifier 215 86
CEMA-d3 quantifier 13.8 218 165
CEMA-d3 qualifier 218 86CEMA correlation with tobacco exposure    93
CEMA excretion was significantly higher in smokers of 
10 mg ISO tar cigarettes compared to smokers of 1 mg 
and  4 mg  ISO  tar  cigarettes  (p<0.001)  (Figure  2).  The 
difference was still significant between smokers of 1 mg 
and 4 mg cigarettes (Figure 2). The number of cigarettes 
smoked daily was not significantly different between the 
1 and 4 mg group and the 4 and 10 mg group (p>0.05), but 
was significantly different between the 1 and 10 mg group 
(Table 5). The number of cigarettes/day, however, is not 
the most reliable indicator of tobacco smoke exposure. 
Therefore the correlation between CEMA and multiple 
cigarette  smoke  exposure  markers  such  as  Tneq  and 
nicotine MLE was also evaluated to determine a dose-
response relationship.
Correlation of urinary CEMA with other biomarkers 
of smoke exposure - Urinary CEMA levels were correlated 
with both, biomarkers of tobacco consumption (urinary 
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Figure 2.  Boxplots of urinary CEMA excretion rates by smoking status 
and ISO tar yields of the smoked cigarettes. Circles represent means, 
centre lines in the boxes represent medians. The upper whisker extends 
to the highest data value within the upper limit (Upper limit = Q3 + 1.5 
(Q3 - Q1), while the lower whisker extends to the lowest value within 
the lower limit (Lower limit = Q1- 1.5 (Q3 - Q1)) where Q1 and Q3 are 
the 25th and 75th percentiles, respectively. Asterisks represent the 
outliers.
Table 5.  Summary statistics for CEMA and selected markers of tobacco smoke exposure in the urine of smokers and non-smokers (NS).
Variable Group n Mean StDev Median Tukey group
cig/day NS 50 0 0 0 -
1mg 48 16.8 6.6 15.0 a
4mg 45 19.2 6.5 18.0 ab
10mg 47 20.1 5.1 20.0 b
3-HPMA (µg/24h) NS 50 228.4 70.4 231.6 a
1mg 48 810.7 559.7 680.4 b
4mg 45 1231.0 687.0 1129.0 c
10mg 47 1945.0 968.0 1806.0 d
Total NNAL (ng/24h) NS 50 12.7 7.5 11.1 a
1mg 48 173.0 125.5 136.7 b
4mg 45 274.1 144.2 276.0 c
10mg 47 486.0 235.5 426.6 d
nicotine MLE (mg/day) NS 50 -a - - -
1mg 48 14.0 8.7 11.5 a
4mg 45 18.4 7.6 19.9 ab
10mg 47 29.9 11.9 28.5 c
Tneq (mg/24h) NS 50 0.0 0.0 0.0 a
1mg 48 7.1 4.8 5.6 b
4mg 45 12.5 6.2 12.1 c
10mg 47 18.8 8.2 17.1 d
CEMA (µg/24h) NS 50 1.3 0.7 1.1 a
1mg 48 96.9 81.8 75.4 b
4mg 45 139.3 72.1 140.2 c
10mg 47 214.8 113.8 186.6 d
a MLE not relevant for non-smokers
Table  4.  Method  performance  for  the  determination  of  CEMA  in 
urine.
Precision Intra-day (n = 10) 5.1 ng/ml 2.60%
150 ng/m 2.00%
278 ng/ml 0.90%
Inter-day (5 days) 5.1 ng/ml 2.90%
150 ng/ml 5.60%
278 ng/ml 4.30%
Accuracy   3.0 ng/ml (n = 4) 102.50%
    150 ng/ml (n = 5) 98.60%
    300 ng/ml (n = 3) 92.40%
LOD   0.06 ng/ml  
LOQ   0.17 ng/ml  
Linearity (LOQ-ULOQ) 2.0-1000ng/ml 
R2  =  0.99975
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Tneq, and nicotine MLE) and biomarkers of smoke toxi-
cants exposure (urinary NNAL and 3-HPMA). Significant 
correlations  (p<0.001)  were  found  between  urinary 
CEMA and all the biomarkers analysed. The correspond-
ing Pearson correlation coefficients (r) are presented in 
Table 6 and the matrix plots for the regression are shown 
in Figure 3.
Discussion
Biomarkers of exposure are widely regarded as the best 
indicators of the level of internal or absorbed dose of a 
toxicant  in  exposed  subjects.  Biomarkers  of  exposure 
are critical for evaluating the impact of new strategies or 
products that aim to reduce exposure to tobacco smoke 
toxicants. In this context, the development of accurate 
methods  and  careful  characterization  of  biomarkers 
specificity,  sensitivity,  and  ability  to  denote  a  dose-
response relationship which is understood on a mecha-
nistic basis is essential (IOM, 2001).
Acrylonitrile is an IARC class 2B carcinogen present in 
tobacco smoke which has been recommended for moni-
toring in tobacco products in the 2008 TobReg proposal 
(Burns et al., 2008). Jakuboswki and colleagues showed 
that  volunteers  who  were  experimentally  exposed  to   
5 or 10 mg/m3 acrylonitrile excreted, on average, 21.8 % 
of the retained dose as CEMA in their urine (Jakubowski 
et al., 1987). However this study was performed with only 
six subjects and the correlation between absorbed dose 
of acrylonitrile and excretion of CEMA gave equivocal 
results. In a recent study, Schettgen and colleagues quan-
tified CEMA in urine of smokers (n = 81), passive smokers 
(n = 38), and non-smokers (n = 73) and demonstrated a 
good correlation between urinary CEMA and cotinine 
levels (Schettgen et al., 2009).
Table 6.  Pearson correlation matrix between CEMA and markers of smoking dose.
Variables cigs/day 3-HPMA (µg/24h) Total NNAL (ng/24h) Nicotine MLE (mg/day) Tneq (mg/24h)
3-HPMA (µg/24h) 0.71 p < 0.001        
Total NNAL (ng/24h) 0.705 p < 0.001 0.865 p < 0.001      
Nicotine MLE (mg/day) 0.727 p < 0.001 0.806 p < 0.001 0.714 p < 0.001    
Tneq (mg/24h) 0.758 p < 0.001 0.913 p < 0.001 0.932 p < 0.001 0.761 p < 0.001  
CEMA (µg/24h) 0.738 p < 0.001 0.885 p < 0.001 0.840 p < 0.001 0.762 p < 0.001 0.869 p < 0.001
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Figure 3.  Scatterplots of CEMA versus biomarkers showing regression lines bordered by 95% prediction intervals. Key to scatterplot groups: ▲ NS, 
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The aim of this work was to further evaluate CEMA as 
a dose-dependent biomarker of acrylonitrile exposure 
using  24h-urine  samples  of  non-smokers  and  smok-
ers of different ISO tar band cigarettes (1 mg, 4 mg, and 
10 mg). CEMA was quantified using a validated LC-MS/
MS method adapted from Schettgen et al, 2009.
Performance  data  for  the  method  complied  with 
the validation criteria of the US FDA (FDA, 2001). In 
particular,  the  LOQ  (0.17 ng/ml)  was  low  enough  to 
allow quantification of CEMA in background exposed 
non-smokers  (Table  4).  Furthermore,  the  column 
switching  technique,  which  consisted  of  an  on-line 
purification and concentration of the analyte prior to 
chromatography on a C8 analytical column, allowed full 
automation of the method resulting in high throughput 
(50–55 samples/day).
Following analysis of the urine samples, the results 
showed that smokers excreted between 75- and 165-
fold  higher  amounts  of  the  acrylonitrile  biomarker 
CEMA  than  non-smokers  (Table  5).  Schettgen  et  al., 
2009 reported urinary median CEMA levels of 2.0 µg/l 
in non-smokers, 3.2-6.6 µg/l in passive smokers, and 
240 µg/l in smokers. Absolute CEMA levels as well as 
smoker/non-smoker ratios (36 – 120, depending on the 
extent of ETS exposure) were in good agreement with the 
results from this study. A rough estimate of the percent-
age of acrylonitrile excreted as CEMA can be calculated 
assuming that: (i) the average smoking pattern is similar 
to the Massachusetts smoking regime, (ii) 50% of the 
acrylonitrile is retained and absorbed through the lungs 
(Jakubowski et al., 1987), (iii) the average background 
exposure to acrylonitrile is reflected by the CEMA level 
observed in non-smokers (1.3 µg CEMA/24hrs urine) 
and is subtracted from CEMA levels in smokers. With 
these assumptions, the percentage of smoking-related 
acrylonitrile  appearing  as  CEMA  in  urine  amount  to 
30.3, 28.5 and 28.7% which is in close agreement with 
the figure provided by Jakubowski et al. (21.8%).
Studies on the smoking-related exposure to acryloni-
trile have been performed in the past with the long-term 
biomarker  of  exposure  CEVal  (cyanoethylvaline)  hae-
moglobin adducts. Smokers were found to have 17- to 
61-fold higher CEVal levels than non-smokers (Fennell 
et al., 1991; Bergmark, 1997; Schettgen et al., 2002, Scherer 
et al., 2007). This is in line with the urinary CEMA data 
and indicates that, with the exception of occupational 
exposures,  acrylonitrile  shows  specificity  for  tobacco 
smoke exposure.
The CEMA results show a strong correlation of the 
acrylonitrile biomarker with various measures of smok-
ing dose, such as daily cigarette consumption, MLE to 
nicotine, and urinary Tneq (r > 0.7, Table 6). This is in 
good agreement with the findings of Schettgen et al., 
2009 who reported a correlation coefficient of r = 0.734 
between CEMA and cotinine in urine. Although cotinine 
is a recognized biomarker for tobacco exposure, its level is 
subject to variability due to metabolic enzyme polymor-
phisms and ethnicity (Bramer and Kallungal, 2003). Total 
nicotine equivalence Tneq is a more reliable measure of 
nicotine consumption as it is the sum of nicotine plus 
five of its metabolites therefore, covering a wider range 
of the total nicotine mass balance. In our study a slight 
improvement in the correlation coefficient was observed 
with a value of r = 0.869 for CEMA and Tneq and r = 0.822 
for CEMA and cotinine.
A  significant  trend  in  urinary  CEMA  levels  with 
increasing ISO tar levels and Tneq was also observed. 
This appears to reflect smoke chemistry measurements, 
which indicates a strong association between ISO tar and 
ISO or Massachusetts acrylonitrile yields of the cigarettes 
used in this study (Table 3).
CEMA was well correlated with other biomarkers of 
tobacco smoke toxicants exposure such as NNAL and 
3-HPMA, two metabolic products of NNK and acrolein, 
respectively.
The confidence intervals in Figure 3 represent the 
range of values inclusive of 95% of the data for all the 
categories confounded. For instance, in 24 hrs urine, 
a 20mg Tneq exposure would potentially correspond 
to a range of 100 to 300 µg CEMA. This illustrates the 
marked  variability  between  data  points,  despite  the 
strong correlation between biomarkers. A number of 
potential sources for the variation can be identified, 
including interindividual variation such as body mass 
index, diet, metabolism and polymorphisms, individual 
smoking and inhalation behavior, samples collection 
and storage, and instrument precision. This underlines 
the importance of an adequate study design to limit 
confounding factors.
In  conclusion,  the  analytical  method  used  for  the 
determination  of  the  urinary  acrylonitrile  biomarker 
CEMA is sufficiently sensitive and specific to detect dif-
ferences  between  smokers  and  non-smokers.  Urinary 
CEMA levels show a clear dose-response relationship to 
the smoking dose, such as daily cigarette consumption, 
MLE to nicotine and urinary Tneq. Finally, CEMA can 
also discriminate between smokers of different ISO tar 
yield cigarettes. The method is therefore appropriate to 
assess the quantitative changes in exposure associated 
with the use of tobacco products, including the switch to 
reduced exposure tobacco products.
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